Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.

HIV Metabolic complications hyperlipidemia pregnancy tenofovir

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 03 06 2024
revised: 23 07 2024
accepted: 29 08 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: aheadofprint

Résumé

Tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) regimens have been associated with adverse changes in lipid and glucose profiles compared with tenofovir disoproxil fumarate (TDF)-based ART, but data in pregnancy is limited. We evaluated metabolic markers in pregnant women with HIV after starting TAF- vs TDF-based ART. We analyzed data within the IMPAACT 2010/VESTED trial, which demonstrated better pregnancy outcomes in pregnant women randomized to initiate TAF/Emtricitabine/Dolutegravir (TAF/FTC+DTG; n=217) or TDF/FTC+DTG (n=215). We measured non-fasting plasma concentrations of glucose, total-cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), lipoprotein (a), and triglycerides from samples collected eight weeks after enrollment. We employed linear regression models to estimate by-arm mean differences. 219 participants enrolled in the DTG arms in Zimbabwe and Uganda: 109 in the TAF/FTC+DTG and 110 in the TDF/FTC+DTG arms. At study entry, mean gestational age was 22.6 weeks, median HIV-1 RNA was 711 copies/mL, and mean age was 25.8 years. By eight weeks, mean total cholesterol was 12 mg/dL higher in women randomized to TAF/FTC+DTG versus TDF/FTC+DTG (95% CI 3.8, 21.1). Pregnant women in the TAF/FTC+DTG arm had higher mean LDL-C (7.1 mg/dL, 95% CI 0.2, 14.0), triglycerides (12.3 mg/dL, 95% CI 1.8, 22.7), lipoprotein (a) (7.3 mg/dL, 95% CI 1.1, 13.6), and lower mean HDL-C (2.8 mg/dL, 95% CI 0.1, 5.6) compared to the TDF/FTC+DTG arm. Pregnant women randomized to start TAF/FTC+DTG had higher lipids than those randomized to TDF/FTC+DTG within eight weeks of ART initiation. However, lipid levels were within normal reference ranges.

Identifiants

pubmed: 39219495
pii: 7747383
doi: 10.1093/cid/ciae441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Sharon Nachman (S)
James McIntyre (J)
David P Harrington (DP)
Catherine Hill (C)
Steven Joffe (S)
Alwyn Mwinga (A)
Andrew J Nunn (AJ)
Haroon Saloojee (H)
Merlin L Robb (ML)
Jonathan Kimmelman (J)
Graeme A Meintjes (GA)
Barbara E Murray (BE)
Stuart Campbell Ray (S)
Haroon Saloojee (H)
Anastasios A Tsiatis (AA)
Paul A Volberding (PA)
David Glidden (D)
Valeria Cavalcanti Rolla (VC)
Nahida Chakhtoura (N)
Renee Browning (R)
Jeanna Piper (J)
Karin Klingman (K)
Debika Bhattacharya (D)
Patrick Jean-Philippe (P)
Lynne Mofenson (L)
Sean Brummel (S)
Lauren Ziemba (L)
Mauricio Pinilla (M)
Chelsea Morroni (C)
Benjamin Johnston (B)
Chelsea Krotje (C)
Scott McCallister (S)
Jean van Wyk (J)
Mark Mirochnick (M)
Brookie Best (B)
Kevin Robertson (K)
Cheryl Blanchette (C)
Nagawa Jaliaah (N)
Andee Fox (A)
Frances Whalen (F)
Kevin Knowles (K)
William Murtaugh (W)
Mauricio Pinilla (M)
Yao Cheng (Y)
Emmanuel Patras (E)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Ahizechukwu C Eke (AC)

Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Sean S Brummel (SS)

Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Muktar H Aliyu (MH)

Department of Health Policy and Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Lynda Stranix-Chibanda (L)

Child and Adolescent Health Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
University of Zimbabwe Clinical Trials Research Centre, Faculty of Medicine and Health Sciences, Harare, Zimbabwe.

George U Eleje (GU)

Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.

Ifeanyichukwu U Ezebialu (IU)

Department of Obstetrics and Gynecology, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Amaku, Anambra State, Nigeria.

Violet Korutaro (V)

Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.

Deo Wabwire (D)

Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda.

Allen Matubu (A)

University of Zimbabwe Clinical Trials Research Centre, Faculty of Medicine and Health Sciences, Harare, Zimbabwe.

Tapiwa Mbengeranwa (T)

University of Zimbabwe Clinical Trials Research Centre, Faculty of Medicine and Health Sciences, Harare, Zimbabwe.

Nahida Chakhtoura (N)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA.

Lameck Chinula (L)

Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill.
UNC Project Malawi, Lilongwe, Malawi.

Katie McCarthy (K)

FHI 360, Durham, North Carolina, USA.

Kevin Knowles (K)

Frontier Science Foundation, Amherst, New York, USA.

Chelsea Krotje (C)

Frontier Science Foundation, Amherst, New York, USA.

Macrae F Linton (MF)

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.

Kelly E Dooley (KE)

Division of Infectious Diseases, Vanderbilt University Medical Center, Department of Medicine, Nashville, Tennessee, United States.

Paul E Sax (PE)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA USA.

Todd Brown (T)

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Shahin Lockman (S)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA USA.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Botswana Harvard Health Partnership, Gaborone, Botswana.

Classifications MeSH